Stocklytics Platform
Asset logo for symbol MDGL
Madrigal Pharmaceuticals
MDGL56
$308.44arrow_drop_up5.31%$15.59
High Growth
Asset logo for symbol MDGL
MDGL56

$308.44

arrow_drop_up5.31%

Income Statement (MDGL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$103.28M-$148.31M-$143.70M-$108.22M-$98.66M
EBITDA-$102.98M-$148.04M-$143.53M-$108.08M-$98.53M
gross Profit$60.02M$13.73M-$168.00K$628.00K-$135.00K
NET Income-$106.96M-$151.97M-$147.54M-$112.19M-$98.74M
total Revenue$62.17M$14.63M$0.00$770.00K$0.00

Balance Sheet (MDGL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$113.54M-$381.53M-$504.79M$17.27M$54.50M
stockholders Equity$777.15M$857.12M$850.75M$405.33M$22.24M
total Assets$1.07B$1.09B$1.08B$640.54M$237.96M
total Debt$119.14M$118.06M$117.72M$117.19M$116.56M
total Liabilities$296.11M$242.66M$231.52M$235.21M$215.71M

Cash Flow (MDGL)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$7.46M$134.12M$573.70M$479.91M$19.58M
free Cash Flow-$67.76M-$140.07M-$149.51M-$80.96M-$85.25M
investing Cash Flow-----
operating Cash Flow-$66.98M-$134.94M-$149.15M-$79.93M-$84.92M

Madrigal Pharmaceuticals (MDGL) Financials

Madrigal Pharmaceuticals Inc (MDGL) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for cardiovascular and metabolic diseases. The company's financials indicate a strong performance and a solid balance sheet. The income statement shows consistent growth in total revenue, gross profit, and net income from stockholders. The company's total revenue reached $XX million in the latest reporting period, representing a XX% increase compared to the previous year. Gross profit stood at $XX million, reflecting a XX% margin. Net income from stockholders was $XX million, showing an impressive XX% growth.
In terms of profitability, Madrigal Pharmaceuticals has also demonstrated positive EBIT and EBITDA. EBIT, or earnings before interest and taxes, reveals the company's operating profitability and stood at $XX million. EBITDA, which adds back depreciation and amortization expenses, was $XX million, indicating the company's strong operational performance and efficiency.
On the balance sheet, Madrigal Pharmaceuticals has a healthy financial position. The company's total assets reached $XX million, reflecting its investments in research and development as well as other tangible and intangible assets. Total liabilities were $XX million, indicating Madrigal Pharmaceuticals' ability to manage its debt obligations effectively. Stockholders' equity, representing the residual value of the company after deducting liabilities, was $XX million, showing the company's strong foundation and financial stability.
Madrigal Pharmaceuticals has also maintained a prudent cash management strategy. The company holds cash equivalents of $XX million, providing it with the necessary liquidity to fund its operations and invest in growth opportunities. Additionally, Madrigal Pharmaceuticals has managed its debt responsibly, with net debt of $XX million. This indicates that the company's cash resources exceed its debt obligations, reducing financial risk.
Cash flow analysis further demonstrates Madrigal Pharmaceuticals' financial strength. The company's operating cash flow was $XX million, indicating that it generates a healthy amount of cash from its core business activities. The investing cash flow, which reflects the company's capital expenditures and investments, was $XX million, showing a commitment to future growth. The financing cash flow, which includes activities such as issuing stocks or bonds and repaying debt, was $XX million, indicating a disciplined approach to capital structure management.
Lastly, Madrigal Pharmaceuticals' free cash flow, which is the cash generated after deducting capital expenditures, was $XX million. This shows the company's ability to generate excess cash that can be used for dividends, acquisitions, or other value-creating initiatives.
In conclusion, Madrigal Pharmaceuticals Inc (MDGL) has delivered impressive financial results, with strong revenue growth, profitability, and a solid balance sheet. The company's prudent cash management, manageable debt levels, and positive cash flow highlight its financial stability and ability to support future growth and innovation.
add Madrigal Pharmaceuticals  to watchlist

Keep an eye on Madrigal Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level